Cargando…
Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750043/ https://www.ncbi.nlm.nih.gov/pubmed/35011594 http://dx.doi.org/10.3390/cells11010032 |
_version_ | 1784631371081187328 |
---|---|
author | Economopoulou, Panagiota Pantazopoulos, Anastasios Spathis, Aris Kotsantis, Ioannis Kyriazoglou, Anastasios Kavourakis, George Zakopoulou, Roubini Chatzidakis, Ioannis Anastasiou, Maria Prevezanou, Maria Resteghini, Carlo Licitra, Lisa Bergamini, Cristiana Colombo, Elena Caspani, Francesca Denaro, Nerina Vecchio, Stefania Bonomo, Pierluigi Cossu Rocca, Maria Bertolini, Federica Ferrari, Daris Psyrri, Amanda Bossi, Paolo |
author_facet | Economopoulou, Panagiota Pantazopoulos, Anastasios Spathis, Aris Kotsantis, Ioannis Kyriazoglou, Anastasios Kavourakis, George Zakopoulou, Roubini Chatzidakis, Ioannis Anastasiou, Maria Prevezanou, Maria Resteghini, Carlo Licitra, Lisa Bergamini, Cristiana Colombo, Elena Caspani, Francesca Denaro, Nerina Vecchio, Stefania Bonomo, Pierluigi Cossu Rocca, Maria Bertolini, Federica Ferrari, Daris Psyrri, Amanda Bossi, Paolo |
author_sort | Economopoulou, Panagiota |
collection | PubMed |
description | Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI. |
format | Online Article Text |
id | pubmed-8750043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87500432022-01-12 Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions Economopoulou, Panagiota Pantazopoulos, Anastasios Spathis, Aris Kotsantis, Ioannis Kyriazoglou, Anastasios Kavourakis, George Zakopoulou, Roubini Chatzidakis, Ioannis Anastasiou, Maria Prevezanou, Maria Resteghini, Carlo Licitra, Lisa Bergamini, Cristiana Colombo, Elena Caspani, Francesca Denaro, Nerina Vecchio, Stefania Bonomo, Pierluigi Cossu Rocca, Maria Bertolini, Federica Ferrari, Daris Psyrri, Amanda Bossi, Paolo Cells Article Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI. MDPI 2021-12-23 /pmc/articles/PMC8750043/ /pubmed/35011594 http://dx.doi.org/10.3390/cells11010032 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Economopoulou, Panagiota Pantazopoulos, Anastasios Spathis, Aris Kotsantis, Ioannis Kyriazoglou, Anastasios Kavourakis, George Zakopoulou, Roubini Chatzidakis, Ioannis Anastasiou, Maria Prevezanou, Maria Resteghini, Carlo Licitra, Lisa Bergamini, Cristiana Colombo, Elena Caspani, Francesca Denaro, Nerina Vecchio, Stefania Bonomo, Pierluigi Cossu Rocca, Maria Bertolini, Federica Ferrari, Daris Psyrri, Amanda Bossi, Paolo Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions |
title | Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions |
title_full | Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions |
title_fullStr | Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions |
title_full_unstemmed | Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions |
title_short | Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions |
title_sort | immunotherapy in nonendemic nasopharyngeal carcinoma: real-world data from two nonendemic regions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750043/ https://www.ncbi.nlm.nih.gov/pubmed/35011594 http://dx.doi.org/10.3390/cells11010032 |
work_keys_str_mv | AT economopouloupanagiota immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT pantazopoulosanastasios immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT spathisaris immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT kotsantisioannis immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT kyriazoglouanastasios immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT kavourakisgeorge immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT zakopoulouroubini immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT chatzidakisioannis immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT anastasioumaria immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT prevezanoumaria immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT resteghinicarlo immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT licitralisa immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT bergaminicristiana immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT colomboelena immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT caspanifrancesca immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT denaronerina immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT vecchiostefania immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT bonomopierluigi immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT cossuroccamaria immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT bertolinifederica immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT ferraridaris immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT psyrriamanda immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions AT bossipaolo immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions |